Drug intelligence / Profile preview

Vaccine Candidate #4

Development stage: Unknown
Lead developer: Pfizer
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics

Overview

**Vaccine Candidate #4** is an unnamed experimental Pfizer mRNA-based influenza vaccine intervention evaluated as one of six vaccine candidates in the Phase 2 study NCT07431853 in healthy adults. Publicly available trial information does not disclose a molecular identifier, encoded influenza antigen, strain composition, valency, lipid nanoparticle composition, or formulation for this specific candidate; therefore, it cannot be reliably resolved to Pfizer's separately identified influenza mRNA program PF-07252220. ([withpower.com](https://www.withpower.com/trial/phase-2-influenza-human-1-2026-0da63))

Beyond the preview

Go deeper on Vaccine Candidate #4.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vaccine Candidate #4.

Explore the full profile